They've got a $624m deal in their pocket, a portfolio of cancer treatments that are making waves in clinical trials and a team that combines scientific acumen with astute commercial strategy.  That's why we've decided to feature Scancell Holdings Plc on our latest episode of Slingshot.  

This week we're privileged to have recently retired CEO Dr Richard Goodfellow to give us the inside scoop on Scancells' journey to biopharma greatness.  Marcus explains what Immuno-oncology is and Charles shares his insight on why the Genmab deal is so validating for Scancell.

Enjoy the episode and let us know what you think.